{
    "ticker": "RVPH",
    "name": "Reviva Pharmaceuticals Holdings, Inc.",
    "description": "Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for major central nervous system (CNS) disorders and other unmet medical needs. Founded in 2011 and headquartered in San Jose, California, Reviva focuses on advancing its lead product candidate, RP5063, which is being investigated for the treatment of schizophrenia and other neuropsychiatric disorders. The company aims to provide safer and more effective therapeutic options for patients suffering from these conditions, with an emphasis on improving quality of life and reducing side effects associated with current treatments. Reviva's proprietary technology platform allows it to develop drugs that target multiple receptors, potentially offering a novel approach to treating complex diseases. The company's mission is to transform patient care through the development of groundbreaking therapies that address the underlying mechanisms of CNS disorders. Reviva is committed to scientific excellence and collaboration, working alongside leading researchers and institutions to advance its drug candidates through the clinical development process.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Jose, California, USA",
    "founded": "2011",
    "website": "https://www.revivapharma.com",
    "ceo": "Laxminarayan B. G. Rao",
    "social_media": {
        "twitter": "https://twitter.com/RevivaPharma",
        "linkedin": "https://www.linkedin.com/company/reviva-pharmaceuticals-holdings-inc/"
    },
    "investor_relations": "https://www.revivapharma.com/investor-relations",
    "key_executives": [
        {
            "name": "Laxminarayan B. G. Rao",
            "position": "CEO"
        },
        {
            "name": "Ravi R. B. Rao",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "CNS Disorders",
            "products": [
                "RP5063"
            ]
        }
    ],
    "seo": {
        "meta_title": "Reviva Pharmaceuticals | Innovative CNS Therapies",
        "meta_description": "Explore Reviva Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing innovative therapies for CNS disorders. Learn about our lead product RP5063 and our mission to improve patient care.",
        "keywords": [
            "Reviva Pharmaceuticals",
            "CNS Disorders",
            "RP5063",
            "Biopharmaceuticals",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Reviva Pharmaceuticals specialize in?",
            "answer": "Reviva Pharmaceuticals specializes in developing innovative therapies for central nervous system disorders."
        },
        {
            "question": "What is RP5063?",
            "answer": "RP5063 is Reviva's lead product candidate being investigated for the treatment of schizophrenia and other neuropsychiatric disorders."
        },
        {
            "question": "Where is Reviva Pharmaceuticals headquartered?",
            "answer": "Reviva Pharmaceuticals is headquartered in San Jose, California, USA."
        },
        {
            "question": "When was Reviva Pharmaceuticals founded?",
            "answer": "Reviva Pharmaceuticals was founded in 2011."
        }
    ],
    "competitors": [
        "ACAD",
        "SAGE",
        "PTLA"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "GILD",
        "AMGN"
    ]
}